Fusion Biopsy Market Size, Share & Trends Analysis Report by Biopsy Route (Transrectal, Transperineal), End-Use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), Region, and Segment - Forecast to 2027
“Increasing prevalence of prostate cancer, rising awareness on importance of regular clinical check-ups, and developing reimbursement policies are factors to boost the fusion biopsy market over the forecast period.”
The global Fusion biopsy market size is projected to reach USD 1,110 million by 2027 from USD 496.5 million in 2022, at a CAGR of 11.2% during the forecast period. Market is driven by factors such as global prevalence of prostate cancer, growing awareness for early disease diagnosis, growing demand in prostate biopsy procedures and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
To know about the assumptions considered for the study, Request for Free Sample Report
“The transrectal segmen accounted for the largest market share in the fusion biopsy market, route type, during the forecast period”
The Fusion biopsy marketis segmented into transrectal biopsy route and transperineal biopsy route . In 2021, transrectal biopsy route accounted for a sizable market share because it was considered as the gold standard in performing prostate biopsy worldwide in the past decades. Most of the commercially available fusion biopsy was limited to the transrectal approach, contributing to its largest market share. However, transperineal biopsy route is expected to increase significantly between 2021 and 2027.
“Hospitals segment accounted for the largest market share, by end user”
Based on end user, the fusion biopsy marketis segmented into hospitals segment, diagnostics centers segment and ambulatory care centers segment . The hospitals segment accounted for the largest market share in 2021, while ambulatory care centers segment is expected to grow at the fastest rate during the forecast period. The rising prevalence of prostate cancer in rural areas having limited access to healthcare services is the factor expected to drive the growth of the segment.
“APAC region accounted for the highest CAGR”
The global fusion biopsy market is divided into five regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East and Africa. According to the regional analysis, the Asia Pacific is anticipated to register the fastest growth in the fusion biopsy market. The Asia Pacific exhibits a lucrative growth opportunity with the emerging economies at the forefront of development. The major factors driving the growth of the market include rising awareness of prostate cancer, increasing population base, and rising disposable income levels as well as high unmet needs of the patients in emerging countries such as India, Japan, and China. The growing unhealthy lifestyles in the region along with the aging population are leading to the growing occurrence of various diseases and cancers. Thus, the growing demand for diagnosis within the region is expected to propel market growth.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6% , and the Middle East & Africa – 4%
To know about the assumptions considered for the study, download the pdf brochure
Lits of Companies Profiled in the Report:
- Eigen
- Koninklijke Philips N.V.
- Hitachi, Ltd.
- MedCom
- ESAOTE SPA
- KOELIS
- Focal Healthcare
- GeoScan Medical
- UC-Care Medical Systems Ltd.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 GROWTH RATE ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing prevalence of prostate cancer
5.2.1.2 Technological advancements in fusion imaging modalities
5.2.1.3 Increasing funds and investments by public and private sector
5.2.2 RESTRAINTS
5.2.2.1 High cost of fusion biopsy system
5.2.2.2 Liquid biopsy system
5.2.3 OPPORTUNITIES
5.2.3.1 Developing countries
5.3 TECHNOLOGY ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER’S FIVE FORCES ANALYSIS
6 GLOBAL FUSION BIOPSY MARKET, BY ROUTE TYPE (USD MILLION)
6.1 INTRODUCTION
6.2 TRANSRECTAL
6.3 TRANSPERINEAL
7 GLOBAL FUSION BIOPSY MARKET, BY END-USER (USD MILLIONS)
7.1 INTRODUCTION
7.2 HOSPITALS
7.3 DIAGNOSTIC CENTERS
7.4 AMBULATORY CARE CENTERS
7.5 OTHER END USERS (IF ANY)
8 GLOBAL FUSION BIOPSY MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 CHINA
8.4.2 JAPAN
8.4.3 INDIA
8.4.4 REST OF ASIA PACIFIC
8.5 LATIN AMERICA
8.6 MIDDLE EAST & AFRICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
9.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
9.4 MARKET SHARE ANALYSIS
9.5 COMPANY EVALUATION QUADRANT
9.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
9.7 COMPETITIVE BENCHMARKING
9.8 COMPETITIVE SCENARIO
10 COMPANY PROFILES
10.1 KEY PLAYERS
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) *
10.1.1 EIGEN
10.1.2 KONINKLIJKE PHILIPS N.V.
10.1.3 HITACHI, LTD.
10.1.4 MEDCOM
10.1.5 ESAOTE SPA
10.1.6 KOELIS
10.1.7 FOCAL HEALTHCARE
10.1.8 GEOSCAN MEDICAL
10.1.9 UC-CARE MEDICAL SYSTEMS LTD.
*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.
11 APPENDIX
11.1 INDUSTRY INSIGHTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
Growth opportunities and latent adjacency in Fusion Biopsy Market